Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges

Zacks03-25

Bayer AG BAYRY presented the latest developments on the road to transform its pharma business to drive growth on its annual Pharma Media Day 2024. The company is now primarily focused on four core ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2422252542?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cCc8LMcWOu520tkUFivbqw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372","is_english":true,"pubTime":"2024-03-25 22:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2422252542","market":"us","top_or_hot":-1,"title":"Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges","media":"Zacks","content":"<div>\n<p>Bayer AG BAYRY presented the latest developments on the road to transform its pharma business to drive growth on its annual Pharma Media Day 2024.\nThe company is now primarily focused on four core ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bayer-bayry-banks-pipeline-progress-140500089.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayer (BAYRY) Banks on Pipeline Progress Amid Challenges\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-25 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bayer-bayry-banks-pipeline-progress-140500089.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bayer AG BAYRY presented the latest developments on the road to transform its pharma business to drive growth on its annual Pharma Media Day 2024.\nThe company is now primarily focused on four core ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bayer-bayry-banks-pipeline-progress-140500089.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1066053197.SGD","symbol_name":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","start_time":0,"source_url":"https://finance.yahoo.com/news/bayer-bayry-banks-pipeline-progress-140500089.html","article_id":"2422252542","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cCc8LMcWOu520tkUFivbqw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2422252542","pubTimestamp":1711375500,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Bayer AG BAYRY presented the latest developments on the road to transform its pharma business to drive growth on its annual Pharma Media Day 2024.The company is now primarily focused on four core therapeutic areas .In 2023, Bayer advanced its pipeline with eight investigational new drug  applications. Four assets are expected to advance to phase II by the end of 2024.The company reported consistently positive top-line data on the pipeline candidate elinzanetant across three phase III studies, OASIS 1, 2 and 3. The candidate is the first dual neurokinin-1,3  receptor antagonist in development as an oral, once-daily, non-hormonal treatment of moderate to severe vasomotor symptoms associated with menopause. Bayer will submit data from these studies to regulatory bodies and expects to launch the drug in 2025.Elinzanetant is a key candidate in Bayer’s pipeline. The successful development and commercialization of elinzanetant is imperative to Bayer, given the recent setbacks.The approval of ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BAYRY":"Bayer A.G.","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4505":"高瓴资本持仓","BK4097":"系统软件","BK4581":"高盛持仓","SG9999001176.USD":"United Global Healthcare Acc USD","PRGS":"Progress Software Corporation","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4588":"碎股","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4592":"伊斯兰概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4585":"ETF&股票定投概念","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4534":"瑞士信贷持仓","BK4139":"生物科技","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BBIO":"BridgeBio Pharma, Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4007":"制药","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","PFE":"辉瑞","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0058720904.USD":"联博国际健康护理基金A","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓"},"translate_title":"拜耳（Bayer）银行在挑战中取得进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":1,"BAYRY":1,"PRGS":1,"PFE":0.9},"content_text":"Bayer AG BAYRY presented the latest developments on the road to transform its pharma business to drive growth on its annual Pharma Media Day 2024.\nThe company is now primarily focused on four core therapeutic areas (cardiovascular diseases, oncology, immunology and neurology & rare diseases).\nIn 2023, Bayer advanced its pipeline with eight investigational new drug (IND) applications. Four assets are expected to advance to phase II by the end of 2024.\nThe company reported consistently positive top-line data on the pipeline candidate elinzanetant across three phase III studies, OASIS 1, 2 and 3. The candidate is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist in development as an oral, once-daily, non-hormonal treatment of moderate to severe vasomotor symptoms associated with menopause. Bayer will submit data from these studies to regulatory bodies and expects to launch the drug in 2025.\nElinzanetant is a key candidate in Bayer’s pipeline. The successful development and commercialization of elinzanetant is imperative to Bayer, given the recent setbacks.\nThe key drug Nubeqa maintains momentum in prostate cancer indication and is on track to reach blockbuster status in 2024. The candidate is being evaluated in other indications.\nThe company is looking to strengthen its portfolio/pipeline through acquisitions and collaborations. \nBayer has strengthened its pharmaceutical research and pipeline in the field of small molecules and precision therapeutics with the acquisition of Vividion.  Vividion advanced the first two high-profile cancer programs, a KEAP 1 activator and STAT3 inhibitor into phase I development in the last six months.\nThe FDA granted Breakthrough Therapy designation to the pipeline candidate BAY 2927088 in February for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer harboring activating HER2 (ERBB2) mutations.\nBayer recently collaborated with Thermo Fisher Scientific Inc. and announced a collaboration to co-develop next-generation sequencing-based companion diagnostic assays for Bayer’s growing precision oncology portfolio.\nBayer, together with its subsidiaries BlueRock and AskBio, is also developing preclinical and clinical cell and gene therapies. The development pipeline comprises seven cell therapy and gene therapy programs in different stages of clinical development.\nAskBio’s gene therapy candidate, AB-1002, for the treatment of congestive heart failure, recently advanced to mid-stage to evaluate its efficacy and safety.\nBlueRock Therapeutics recently released positive 18-month data from the stem cell-derived investigational therapy bemdaneprocel (BRT-DA01) in patients with Parkinson’s disease. Plans to initiate a phase II study in 2024 are on track. An additional gene therapy candidate in patients with Parkinson’s disease is expected to enter phase II later this year.\nThe approval of Eylea (aflibercept) 8 mg in key markets such as the European Union, Japan, Canada and the UK earlier this year has strengthened its portfolio.\nAnother key growth driver is Kerendia / Firialta (finerenone), approved for the treatment of chronic kidney disease associated with type 2 diabetes. The drug is performing well in the United States, China and Mexico. Bayer believes the drug has blockbuster potential.\nPipeline setbacks and regulatory setbacks have weighed on the stock in recent times. The late-stage study, OCEANIC-AF, investigating asundexian compared with direct oral anticoagulant Eliquis (apixaban) in patients with atrial fibrillation and at risk for stroke, was stopped early due to the lack of efficacy. This was a major setback, given the candidate’s potential.\nPfizer PFE has collaborated with Bristol Myers Squibb for Eliquis.\nMoreover, one of the top drugs in the pharmaceutical division, Xarelto, is facing generic competition. The ongoing glyphosate litigation in the United States has adversely impacted Bayer’s cash position due to high legal costs.\nFollowing a review of the company’s capital allocation priorities to reduce debt, BAYRY plans to amend its dividend policy to pay out only the legally required minimum for three years.\nBayer recently acquired marketing rights for the cardiovascular candidate acoramidis in Europe from BridgeBio BBIO. The rights were acquired from Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V.\nA new drug application for acoramidis has been filed with the FDA, and the regulatory body has set a target action date of Nov 29, 2024 for the same. Per the terms of the agreement, BridgeBio and the affiliates will receive an upfront payment of $310 million from Bayer.\nUpon potential approval, acoramidis will compete with Pfizer’s Vyndaqel.\nIn light of these challenges, Bayer is implementing a new operating model to reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes. The company is also undertaking significant job cuts. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nPfizer Inc. (PFE) : Free Stock Analysis Report\nBayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report\nBridgeBio Pharma, Inc. (BBIO) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422252542"}